Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients

(2014) Marios Politis et al.   JOURNAL OF CLINICAL INVESTIGATION

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia

(2013) Erwan Bezard et al.   MOVEMENT DISORDERS

Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease

(2012) M. A. Cenci et al.   CNS & Neurological Disorders-Drug Targets

Pharmacokinetic evaluation of eltoprazine

(2011) Sharon B Wigal et al.   Expert Opinion on Drug Metabolism & Toxicology

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial

(2011) Hideyuki Sawada et al.   PLoS One

Systematic review of levodopa dose equivalency reporting in Parkinson's disease

(2010) Claire L. Tomlinson et al.   MOVEMENT DISORDERS

Parkinson's disease

(2009) Andrew J Lees et al.   LANCET

Placebo influences on dyskinesia in Parkinson's disease

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS

Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism

(2008) X. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA